Raltegravir: Difference between revisions
ClaireLewis (talk | contribs) |
|||
| Line 55: | Line 55: | ||
*https://www.uptodate.com/contents/raltegravir-drug-information?search=Raltegravir&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1#F5374911 | *https://www.uptodate.com/contents/raltegravir-drug-information?search=Raltegravir&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1#F5374911 | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Latest revision as of 22:15, 23 September 2019
Administration
- Type: Antiretroviral, Integrase inhibitor
- Dosage Forms: 400 mg, 600 mg tablet
- Routes of Administration: PO
- Common Trade Names: Isentress
Adult Dosing
Recommended as part of a regimen including Tenofovir plus Emtricitabine or Lamivudine
- Treatment-naive: 400 mg BID or 1200 mg daily
- Treatment-experienced: 400 mg BID
Pediatric Dosing
Oral suspension (10 mg/mL): 6 mg/kg/dose BID
- Maximum dose: 100 mg/dose
Special Populations
- Pregnancy Rating: C
- Lactation risk: Unknown
Renal Dosing
- Mild to Moderate renal disease: No dosage adjustment necessary
- ESRD on HD: Dose after dialysis on dialysis days
Hepatic Dosing
No dosage adjustment necessary
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Stevens-Johnson Syndrome
- Anaphylaxis
- Myopathy/Rhabdomyolysis
Common
- Hepatic- increased transaminases
Pharmacology
- Half-life: 9 hours
- Metabolism: Hepatic glucuronidation
- Excretion: Renal
Mechanism of Action
- Reverse transcriptase inhibitor